IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces a Class Action Lawsuit Against Ophthotech Corporation and Advises Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ophthotech Corporation (“Ophthotech” or the “Company”) (Nasdaq: OPHT) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Ophthotech shares between May 11, 2015 and December 12, 2016 inclusive (the “Class Period”), are encouraged to contact the firm prior to March 13, 2017, also known as the lead plaintiff motion deadline

If you purchased or otherwise acquired Ophthotech shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

According to the Complaint, Ophthotech rendered exaggerated positive reports regarding the effectiveness and potential of its treatment Fovista, used in combination with Lucentis, an anti-vascular endothelial growth factor agent, despite knowledge that the phase 3 clinical trial of Fovista would be unsuccessful in achieving its primary endpoint. According to the Complaint, these statements caused Ophthotech stock to trade at artificially inflated prices. On December 12, 2016, Ophthotech revealed that the trial could not achieve its primary endpoint. When this information was released to the public, the value of Ophthotech stock fell sharply, causing investors severe harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170119005802/en/